On November 14, 2024, Humacyte, Inc. announced the pricing of a registered direct offering, agreeing to sell approximately $15.0 million worth of its common stock and warrants to an institutional investor. The offering includes 2,808,988 shares of common stock and warrants to purchase an equal number of shares.
The warrants are immediately exercisable at an exercise price of $5.34 per share, with half expiring in 180 days and the other half in four and a half years. The purchase price for one share of common stock and one warrant is $5.34.
The gross proceeds from this offering are estimated to be approximately $15.0 million before deducting offering expenses. This capital infusion is intended to support the company's ongoing clinical programs and operational needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.